<i>TERT</i> promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinoma
In this retrospective study, TPM or TERT OE identifies a more aggressive subset of patients with poor OS and an immune-evasive microenvironment but a better response to immunotherapy in aUC.
Authors
- Kaifeng Jin (ORCID: https://orcid.org/0000-0001-9867-6516)
- Jingtong Xu (ORCID: https://orcid.org/0009-0007-5041-5860)
- Zewei Wang (ORCID: https://orcid.org/0000-0002-8833-3541)
- Zhaopei Liu (ORCID: https://orcid.org/0000-0002-5288-5037)
- Yawei Ding (ORCID: https://orcid.org/0000-0002-2879-3642)
- Jiejie Xu (ORCID: https://orcid.org/0000-0001-7431-9063)
- Ziyue Xu (ORCID: https://orcid.org/0009-0000-1305-6191)
- Xiaohe Su (ORCID: https://orcid.org/0009-0006-4951-2236)
- Yu Zhu (ORCID: https://orcid.org/0000-0002-3332-5202)
- Hailong Liu (ORCID: https://orcid.org/0000-0002-6181-2577)
- Yuan‐Shiun Chang
- Lingkai Zhang (ORCID: https://orcid.org/0000-0003-1291-6203)
- Le Xu (ORCID: https://orcid.org/0000-0002-9727-7713)
Institutions
- Sun Yat-sen University (CN)
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- XinHua Hospital (CN)
- Ruijin Hospital (CN)
- Fudan University Shanghai Cancer Center (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- BMJ Oncology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/bmjonc-2024-000586
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Gilead Sciences
- Natural Science Foundation of Shanghai
- Shanghai Anti-Cancer Association
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Shanghai Education Development Foundation
- Fudan University
- Shanghai Municipal Education Commission
- Shanghai Municipal Health Bureau